SYM FINANCIAL Corp Buys 1,509 Shares of Johnson & Johnson (NYSE:JNJ)

SYM FINANCIAL Corp grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,559 shares of the company's stock after purchasing an additional 1,509 shares during the period. SYM FINANCIAL Corp's holdings in Johnson & Johnson were worth $1,585,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Accredited Investors Inc. increased its stake in Johnson & Johnson by 3.8% during the 1st quarter. Accredited Investors Inc. now owns 8,514 shares of the company's stock valued at $1,412,000 after buying an additional 315 shares during the period. M. Kulyk & Associates LLC boosted its holdings in shares of Johnson & Johnson by 5.0% in the first quarter. M. Kulyk & Associates LLC now owns 1,889 shares of the company's stock worth $313,000 after buying an additional 90 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new position in shares of Johnson & Johnson in the first quarter worth about $4,535,000. KLP Kapitalforvaltning AS boosted its holdings in shares of Johnson & Johnson by 3.4% during the first quarter. KLP Kapitalforvaltning AS now owns 1,083,614 shares of the company's stock worth $179,707,000 after purchasing an additional 35,800 shares during the period. Finally, Summit Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 4.4% during the first quarter. Summit Asset Management LLC now owns 15,582 shares of the company's stock worth $2,584,000 after purchasing an additional 652 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.7%

Shares of Johnson & Johnson stock traded down $1.27 during trading on Friday, hitting $168.29. 6,199,690 shares of the company were exchanged, compared to its average volume of 8,375,731. The firm has a market capitalization of $404.92 billion, a P/E ratio of 18.00, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm's fifty day moving average price is $156.08 and its 200 day moving average price is $155.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday. Bank of America raised their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.